Vepsitamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration vepsitamab binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.

**Synonyms:** - AMG 199 - AMG199 - Anti-MUC17 x Anti-CD3 BiTE AMG 199 - Anti-MUC17/CD3 BiTE Antibody AMG 199 - Anti-MUC17/CD3 Bispecific Antibody AMG 199 - BiTE Antibody AMG 199 - Bispecific T-cell Engager Antibody AMG 199 - MUC17/CD3-directed Bispecific T-cell Engager Antibody AMG 199 - MUC17xCD3 Bispecific T-cell Engager AMG 199 - VEPSITAMAB